Black ginger Kaempferia parviflora Wall. ex Baker
Also called: Kaempferia rubromarginata (synonym), Stahlianthus rubromarginatus (synonym)
Black ginger is a Southeast Asian plant whose rhizome extracts are rich in methoxylated flavones. It has been used traditionally to promote well-being and is now sold as an extract supplement, notably in Japan.
- Category
- Botanical
- Part used
- Rhizome (extracts)
- Strongest evidence
- C Limited
- Native range
- Native from southeastern Bangladesh to Indo-China (POWO lists Bangladesh, Cambodia, Myanmar and Thailand)
- Reviewed
- 2026-10-29
Class 1 Well studied in people. A 2017 systematic review found 7 RCTs of Kaempferia parviflora alone (6 oral, 1 a skin cream; only 2 could be pooled). This entry cites 3 later oral placebo-controlled RCTs, one using a purified polymethoxyflavone fraction. Oral rhizome-extract trials total 8 RCTs (Class 2). [9]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBlood sugar and weight3 topics
CMuscles and exercise1 topic
CHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Visceral fat in overweight Japanese adults | C | One 12-week placebo-controlled RCT (80 adults; 12 mg/day purified polymethoxyflavone) reported lower visceral and total fat area on CT than placebo. [3] |
| Body fat in overweight Korean adults | C | One 12-week placebo-controlled RCT (83 adults analyzed) of a different Kaempferia parviflora extract reported lower body fat, weight and BMI than control, with no difference in waist or hip circumference. [6] |
| Fasting blood glucose | C | A 2024 meta-analysis pooling animal studies and RCTs found lower fasting glucose in human studies (SMD -0.51, 95% CI -0.98 to -0.05). [4] |
| Physical fitness in adolescent athletes | C | One 12-week RCT in 194 male student-athletes (360 mg/day) reported greater grip and back-leg strength, VO2 max and sprint speed, with no change in flexibility or agility. [5] |
| Sexual function | C | A 2024 meta-analysis that pooled animal studies and RCTs reported improved sexual function; its abstract does not report human results for this outcome separately. [4] |
Main constituents: Polymethoxyflavones; 5,7-dimethoxyflavone and 3,5,7,3',4'-pentamethoxyflavone are named as main ingredients of the extract [1]; Nine flavones detected by UPLC-QTOF-MS in rhizome extracts [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 12 mg polymethoxyflavone per day from purified extract for 12 weeks. [3]
- 360 mg/day of a standardized extract for 12 weeks in adolescent athletes. [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines1 listed
Midazolam and other CYP3A substrates
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
Interactions
| With | What happens |
|---|---|
| Midazolam and other CYP3A substrates | Extract inhibited CYP3A-mediated midazolam metabolism in human liver microsomes and raised midazolam AUC 2.3-fold in rats; not yet studied in people. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- 5,7-dimethoxyflavone content of extracts can be measured by HPLC; extract composition varied with solvent. [2]
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements or their labeling; under DSHEA it has no authority to approve them before they are marketed, and firms are responsible for their products' safety and labeling. [7]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- 5,7-dimethoxyflavone and 3,5,7,3',4'-pentamethoxyflavone (polymethoxyflavones) Flavonoids (methoxylated flavones) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming black ginger (Kaempferia parviflora) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of black ginger (Kaempferia parviflora) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Midazolam and other CYP3A substrates: Extract inhibited CYP3A-mediated midazolam metabolism in human liver microsomes and raised midazolam AUC 2.3-fold in rats; not yet studied in people. [P1]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component before use — 21 CFR 111.75(a)(1)(i) requires at least one appropriate identity test or examination unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P4]
- HPLC assay of 5,7-dimethoxyflavone — Named as a main ingredient of the extract; HPLC was used to quantify it in rhizome extracts. [P5]
Supply and conservation
- IUCN Red List: Data Deficient (DD), via GBIF species API, retrieved 2026-10-29 [P6]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Kashiwabuchi Y, et al. Inhibition of CYP3A-mediated midazolam metabolism by Kaempferia parviflora. Food Saf (Tokyo) 2022;10(1):32-41 (PMID 35510070), 2022-03-03. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs on the Identification of Carcinogenic Hazards to Humans. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, checked 2026-10-29), 2026-10-29. ecfr.gov
- Sitthichai P, et al. Kaempferia parviflora rhizome extract as potential anti-acne ingredient. Molecules 2022 (PMID 35889274), 2022-07-08. pubmed.ncbi.nlm.nih.gov
- GBIF species API: IUCN Red List category for Kaempferia parviflora, 2026-10-29. api.gbif.org
Sources
- Kashiwabuchi Y, et al. Inhibition of CYP3A-mediated midazolam metabolism by Kaempferia parviflora. Food Saf (Tokyo) 2022;10(1):32-41 (PMID 35510070), 2022-03-03. pubmed.ncbi.nlm.nih.gov
- Sitthichai P, et al. Kaempferia parviflora rhizome extract as potential anti-acne ingredient. Molecules 2022 (PMID 35889274), 2022-07-08. pubmed.ncbi.nlm.nih.gov
- Yoshino S, et al. Polymethoxyflavone purified from Kaempferia parviflora reduces visceral fat in Japanese overweight individuals: a randomised, double-blind, placebo-controlled study. Food Funct 2021;12(4):1603-1613 (PMID 33475663), 2021-03-01. pubmed.ncbi.nlm.nih.gov
- Na Takuathung M, et al. A systematic review and meta-analysis of animal and human studies demonstrates the beneficial effects of Kaempferia parviflora on metabolic syndrome and erectile dysfunction. Nutr Res 2024;122:80-91 (PMID 38194854), 2024-02. pubmed.ncbi.nlm.nih.gov
- Sripanidkulchai B, et al. Supplementation of Kaempferia parviflora extract enhances physical fitness and modulates parameters of heart rate variability in adolescent student-athletes: a randomized, double-blind, placebo-controlled clinical study. J Diet Suppl 2022;19(2):149-167 (PMID 33272042), 2022. pubmed.ncbi.nlm.nih.gov
- Sung HK, et al. Kaempferia parviflora extract (SIRTMAX) reduces body fat in adults who are overweight: a 12-week randomized, double-blind, placebo-controlled trial. Front Nutr 2025;12:1576024 (PMID 40661686), 2025-06-25. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Kaempferia parviflora Wall. ex Baker (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
- Saokaew S, et al. Clinical effects of Krachaidum (Kaempferia parviflora): a systematic review. J Evid Based Complementary Altern Med 2017;22(3):413-428 (PMID 27694558), 2016-09-30. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.